A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Provided are a novel amylose derivative which exhibits excellent optical isomer separability and which is suitable as an optical isomer separating agent; and an optical isomer separating agent containing the amylose derivative. A task is attained by an amylose derivative having a constituent unit represented by formula (I) below; In below formula (I), R.sup.1 is a substituent group represented by any of formulae 1 to 3 below, and R.sup.2 is a substituent group represented by any of formulae a to g below. R.sup.1 and R.sup.2 are different substituent groups. A combination of R.sup.1 and R.sup.2 in which R.sup.1 is a substituent group represented by structural formula 3 and R.sup.2 is a substituent group represented by structural formula c is excluded from the formula (I).

##STR00001##

Provided are a novel amylose derivative which exhibits excellent optical isomer separability and which is suitable as an optical isomer separating agent; and an optical isomer separating agent containing the amylose derivative. A task is attained by an amylose derivative having a constituent unit represented by formula (I) below; In below formula (I), R.sup.1 is a substituent group represented by any of formulae 1 to 3 below, and R.sup.2 is a substituent group represented by any of formulae a to g below. R.sup.1 and R.sup.2 are different substituent groups. A combination of R.sup.1 and R.sup.2 in which R.sup.1 is a substituent group represented by structural formula 3 and R.sup.2 is a substituent group represented by structural formula c is excluded from the formula (I).

##STR00001##

Provided are a novel amylose derivative which exhibits excellent optical isomer separability and which is suitable as an optical isomer separating agent; and an optical isomer separating agent containing the amylose derivative. A task is attained by an amylose derivative having a constituent unit represented by formula (I) below; In below formula (I), R.sup.1 is a substituent group represented by any of formulae 1 to 3 below, and R.sup.2 is a substituent group represented by any of formulae a to g below. R.sup.1 and R.sup.2 are different substituent groups. A combination of R.sup.1 and R.sup.2 in which R.sup.1 is a substituent group represented by structural formula 3 and R.sup.2 is a substituent group represented by structural formula c is excluded from the formula (I). ##STR00001##

Provided are a novel amylose derivative which exhibits excellent optical isomer separability and which is suitable as an optical isomer separating agent; and an optical isomer separating agent containing the amylose derivative. A task is attained by an amylose derivative having a constituent unit represented by formula (I) below; In below formula (I), R.sup.1 is a substituent group represented by any of formulae 1 to 3 below, and R.sup.2 is a substituent group represented by any of formulae a to g below. R.sup.1 and R.sup.2 are different substituent groups. A combination of R.sup.1 and R.sup.2 in which R.sup.1 is a substituent group represented by structural formula 3 and R.sup.2 is a substituent group represented by structural formula c is excluded from the formula (I). ##STR00001##

A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.